

Doctor

José Luis Salazar

Director de Nuevas Creaciones (C)

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

E. _____ S. _____ D. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 08-052929-A-00002-0000

Fecha: 2013-03-13 16:11:56 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 523 RESPUESTA Folios: 69

Referencia: Expediente No. 08.052.929 A

Solicitud de Patente de Invención titulada: "Compuestos de benzamidilos como inhibidores de la proteína de transferencia de éster de coleserilo".

Solicitante: Bristol-Myers Squibb Company

RESPUESTA AL AUTO NOTIFICADO POR FIJACIÓN EN LISTA No.450
DEL 18 DE DICIEMBRE DE 2012, OFICIO NO. 23228 (EXAMEN DE FONDO)

ÁLVARO CORREA ORDÓÑEZ, mayor de edad y vecino de Bogotá D.C., identificado tal como aparece al pie de mi firma, en mi carácter de apoderado de la sociedad en referencia, doy respuesta al auto emanado por ese Despacho dentro del término legal:

1. Objeciones del Examinador

1.1 Claridad de la solicitud

Con relación a las reivindicaciones 1 y 2 el examinador menciona que no están definidas por su estructura central químicamente definida. Establecé además que aunque las reivindicaciones tienen definiciones para A, B, C y R1, estas tienen una excesiva cantidad

de posibilidades para sustituir el anillo fenilo. El examinador sugiere, restringir la solicitud a una razonable generalización del tipo de compuestos que ha sido sintetizado o probado.

La reivindicación 4 define la composición en términos de agentes terapéuticos como inhibidores de reductasa HMG-CoA, inhibidores de síntesis de colesterol (...), pero estos corresponden a grupos farmacológicos. Por lo tanto, se considera que tal reivindicación se refiere a todos los fármacos que pertenecen a cada grupo de agentes terapéuticos. El examinador sugiere definir bajo la denominación común internacional o nombre IUPAC, los principios activos usados como agentes terapéuticos y que fueron objeto de comprobación para el caso de la composición de la presente solicitud.

1.2 Unidad de Invención

El examinador menciona que la solicitud no cumple con el requisito de unidad de invención porque se refiere a 5 grupos inventivos. Su Despacho sugiere presentar las solicitudes divisionales que considere necesarias o limitar la solicitud inicial a una sola invención, eliminando de ella las otras invenciones.

1.3 Nivel inventivo

El Examinador establece que los documentos **D1** (US5605916) y **D2** (US4798687) afectan el nivel inventivo de las reivindicaciones 1 a 3. En forma resumida el examinador argumenta lo siguiente:

"Los documentos D1 y D2 se consideran el estado de la técnica cercano a la invención en la reivindicación 1 porque el documento 1 divulga la fórmula estructural general de compuestos que tienen un carbono central enlazado a los siguientes sustituyentes: una amida secundaria sustituida con alquilamina, un hidrógeno, un fenilo y un alquilfenilo (...)

La diferencia entre la invención definida en la reivindicación 1 y la fórmula estructural de D1, corresponde a que la invención tiene un fenilo sustituido en el radical B.

La diferencia entre la invención, definida en la reivindicación 1 y la fórmula estructural del documento D2, corresponde a que la invención tiene un fenilo en el radical A.

No se evidencia que por el hecho de tener un fenilo sustituido en el radical B, se tenga un efecto técnico inesperado (...)

En consecuencia, la persona del oficio normalmente versada en la materia, incluiría un fenilo sustituido en el radical B, empleando las fórmulas estructurales de los documentos D1 y D2, para llegar así al objeto de la reivindicación 1 de la solicitud, por lo que la materia reivindicada se deriva evidentemente a partir del estado de la técnica o es obvia a partir de las enseñanzas de los documentos".

2. Argumentos a favor de la patentabilidad de la solicitud

2.1 Modificación a una solicitud en trámite

Con el objeto de atender a las observaciones del examinador y de conformidad con el artículo 34 de la Decisión 486 que permite al solicitante efectuar modificaciones a su solicitud en cualquier momento del trámite sin que se presente ampliación de la invención originalmente presentada, me permito presentar un nuevo pliego reivindicatorio como sustituto del originalmente presentado conformado por tres reivindicaciones.

2.2 Claridad de la solicitud

El examinador podrá notar que la reivindicación 4 fue cancelada y las reivindicaciones 1 y 2 se limitaron significativamente. Las modificaciones están totalmente sustentadas en la memoria descriptiva originalmente presentada, por ejemplo, en las reivindicaciones originales y en los ejemplos.

Con relación al alcance de las reivindicaciones, informamos a su Despacho que con el nuevo pliego reivindicatorio se da por superada la anterior observación, ya que el alcance de los sustituyentes A, B, C, y R₁ se modificó de tal forma que siguen los tipos de los compuestos revelados en los ejemplos de la solicitud en estudio.

De esta forma se da por superada la anterior observación.

2.3 Unidad de invención

Informamos a su Despacho que con las modificaciones efectuadas al pliego reivindicatorio se da por superada esta observación ya que el alcance de las reivindicaciones se definió de manera similar al segundo grupo establecido por el examinador.

Específicamente, las reivindicaciones se han modificado por medio del cual A contiene un grupo alquilo o cicloalquiloxi fenilo sustituido; B contiene un grupo alquiloxi sustituido; C contiene un alquilo unido al grupo fenilo opcionalmente sustituido con halógeno, alquilo, alquiloxi o hidroxilo; y R_1 es $-C(O)R_3$ donde R_3 es fenilo sustituido.

De esta forma se da por superada esta observación, ya que el nuevo pliego reivindicatorio se refiere solamente a un grupo inventivo.

2.4 Nivel inventivo

El nivel inventivo de una solicitud se encuentra definido en el Artículo 18 de la Decisión 486 y se establece cuando *“si para una persona del oficio normalmente versada en la materia técnica correspondiente, esa invención no hubiese resultado obvia ni se hubiese derivado de manera evidente del estado de la técnica”*.

Contrario a lo que plantea el Examinador, el documento del arte previo citado **D1** (US5605916) y **D2** (US4798687) no afecta el nivel inventivo de la presente solicitud por cuanto no es posible derivar la presente invención a partir de las enseñanzas presentadas en dichos documentos.

Para demostrar la anterior afirmación, mi representada presenta los siguientes argumentos:

D1 (US 5605916)

Los compuestos tal como ahora se reivindican, son inventivos con respecto a **D1** ya que **D1** falla en revelar los compuestos de la presente invención tal como se establecen en las reivindicaciones modificadas. Por ejemplo, **D1** revela compuestos en los cuales el

sustituyente R_1 , el cual sería el sustituyente correspondiente a B de la presente invención, es hidrógeno, alquilo C_{1-6} o alcóxicarbonilo C_{1-6} . Por el contrario, los compuestos como se reivindican en las reivindicaciones modificadas requieren que el sustituyente B sean un grupo fenilo sustituido.

Adicionalmente, D1 no permite un sustituyente correspondiente a R_3 de la presente que sea un grupo fenilo sustituido. Por el contrario, en D1 el sustituyente correspondiente a R_3 de la presente invención es $-CH_2NH_2$. Por el contrario, los compuestos tal como se reclaman en las reivindicaciones corregidas requieren que R_3 sea un grupo fenilo sustituido.

Además, en ninguna parte D1 se enseña o sugiere que los compuestos puedan exhibir actividad farmacológica relacionada con la inhibición de la proteína de transferencia de éster de colesterol (CETP). Por el contrario, los compuestos de D1 se revelan que tienen propiedades anticonvulsivas, tranquilizantes y neuroprotectoras.

Adicionalmente, en ninguna parte de D1 se enseña o se sugiere que los compuestos serían efectivos en tratar arteriosclerosis, trombosis venosa, enfermedad vascular periférica, dislipidemia, hiperbetalipoproteinemia, hipoalfalipoproteinemia, hipercolesterolemia, hipertrigliceridemia, hipercolesterolemia familiar, desórdenes cardiovasculares, angina, isquemia, isquemia cardíaca, infarto, infarto miocárdico, daño de reperfusión, restenosis angioplástica, hipertensión, complicaciones vasculares de diabetes, obesidad o endotoxemia, inhibición de la producción de lipoproteína remanente o elevación del colesterol HDL en un mamífero. En contraste, los compuestos de D1 se describen como útiles para tratar enfermedades como el derrame cerebral, isquemia cerebral, parálisis cerebral, hipoglucemia, epilepsia, enfermedad de Alzheimer, corea de Huntington, atrofia olivopontocerebelosa, asfixia y anoxia perinatal. De acuerdo con las anteriores diferencias, se considera que la presente invención como se establece en las reivindicaciones modificadas es inventiva con relación al documento D1.

Con relación al documento D2 (US 4798687)

Mi representada argumenta que los compuestos tal como ahora se reivindican son inventivos con respecto a D2, ya que D2 falla en revelar los compuestos de la presente invención tal como se establecen en las reivindicaciones modificadas. Por ejemplo, D2

revela compuestos en los cuales el sustituyente correspondiente a A de la presente invención tiene que ser $-CF_3$. Por el contrario, los compuestos como se reivindican en las reivindicaciones modificadas requieren que el sustituyente A sea un grupo fenilo sustituido.

En ninguna parte del documento D2 se enseña o sugiere que el sustituyente correspondiente a A de la presente invención sea otra cosa que $-CF_3$. Adicionalmente, D2 no permite un sustituyente correspondiente a R_3 de la presente que sea un grupo fenilo sustituido. Por el contrario, en D2 el sustituyente correspondiente a R_3 de la presente invención es un aminoalquilo, monoalquilaminoalquilo C1-4, dialquilaminoalquilo C2-8, un ciclopropilaminoalquilo, 1-pirrolidinilalquilo, y 1-piperidinilalquil o el grupo 4-morfolinilalquilo. Por el contrario, los compuestos tal como se reclaman en las reivindicaciones corregidas requieren que R_3 sea un grupo fenilo sustituido. Adicionalmente, en ninguna parte D2 se enseña o sugiere que los compuestos puedan exhibir actividad farmacológica relacionada con la inhibición de la proteína de transferencia de éster de colesterilo (CETP). Por el contrario, los compuestos de D2 se revelan como que tienen propiedades antiepilépticas. En vista de las anteriores diferencias, se considera que la presente invención tal como se establece en las reivindicaciones modificadas es inventiva con relación a D2.


En este orden de ideas, tenemos que la invención propuesta por el solicitante además de ser novedosa como ya lo ha reconocido su Despacho también cumple con el requisito de nivel inventivo y de esta manera es susceptible de ostentar el título de patente de invención.

3. Solicitudes concedidas en otros países para esta misma invención.

A manera informativa, pongo en conocimiento del Examinador que la patente EP 1 954 668 equivalente a la presente solicitud colombiana ha sido otorgada. Aún cuando entiendo que esta decisión de ninguna manera obliga al Despacho para decidir de igual forma, considero que por tratarse de una pregunta fáctica la determinación de la existencia de novedad, nivel inventivo y aplicación industrial, las decisiones de otras oficinas de patentes constituyen un antecedente persuasivo en la materia.

En virtud de lo anterior, solicito que se acepten las razones expuestas en el presente documento y en consecuencia, se otorgue el privilegio de patente de invención para el invento que se tramita en este expediente.

Atentamente,




ÁLVARO CORREA ORDÓÑEZ
C.C. No. 79.143.366 de Usaquén
T.P. 20.281

Anexos: - Capítulo reivindicatorio modificado conformado por 3 reivindicaciones
 - Copia de la carátula y reivindicaciones de la Patente EP 1 954 668

BOGMGT/BOGDMS-#1424593-V1-P2008_000210A-0720.DOC


Reivindicaciones modificadas de la solicitud No. 08.052.929 A


- Un compuesto de la formula Ia o Ib




o esteroisómeros o formas de sal farmacéuticamente aceptables de los mismos, donde:


A es:









B es:



C es:




2. Un compuesto del a formula Ia





Ia

o esteroisómeros o formas de sal farmacéuticamente aceptables de los mismos, donde:


A es:





























B es:








C es:



16



- BOGMGT/BOGDMS-#1419860-V1-P2008_000210A-REIVINDICACIONES_FINAL.DOCX



(11) **EP 1 954 668 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Claims DE 3
Claims EN 3
Claims FR 3

(48) Corrigendum issued on:
21.03.2012 Bulletin 2012/12

(45) Date of publication and mention of the grant of the patent:
28.09.2011 Bulletin 2011/39

(21) Application number: 06839913.8

(22) Date of filing: 16.11.2006
- (51) Int Cl.:
C07C 211/29 (2006.01) C07C 215/08 (2006.01)
C07C 217/58 (2006.01) C07C 229/36 (2006.01)
C07C 229/38 (2006.01) C07C 233/09 (2006.01)
C07C 233/13 (2006.01) C07C 233/18 (2006.01)
C07C 233/56 (2006.01) C07C 233/60 (2006.01)
C07C 233/66 (2006.01) C07C 233/73 (2006.01)
C07C 233/78 (2006.01) C07C 235/20 (2006.01)
C07C 235/34 (2006.01)

(86) International application number:
PCT/US2006/060958

(87) International publication number:
WO 2007/062308 (31.05.2007 Gazette 2007/22)

(54) **HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS**
ALS CETP-HEMMER GEEIGNETE HOMO- UND HETEROCYCLISCHE VERBINDUNGEN
COMPOSÉS HOMO- ET HÉTÉROCYCLIQUES UTILES COMME INHIBITEURS DE CETP

- (84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR
Designated Extension States:
HR MK RS

(30) Priority: 23.11.2005 US 739374 P
13.11.2006 US 558979

(43) Date of publication of application:
13.08.2008 Bulletin 2008/33

(73) Proprietor: Bristol-Myers Squibb Company
Princeton, NJ 08543-4000 (US)

(72) Inventors:
• SALVATI, Mark E.
Pennington, New Jersey 08534 (US)
• FINLAY, Heather
Pennington, New Jersey 08534 (US)
• CHEN, Bang-chi
Princeton, New Jersey 08543 (US)
• HARIKRISHNAN, Lalgudi S.
Princeton, New Jersey 08543 (US)
• JIANG, Ji
Pennington, New Jersey 08534 (US)
- JOHNSON, James A.
Pennington, New Jersey 08534 (US)
 - KAMAU, Muthoni G.
Princeton, New Jersey 08543 (US)
 - LAWRENCE, Michael R.
Pennington, New Jersey 08534 (US)
 - LI, Jianqing
Wallingford, Connecticut 06492 (US)
 - LLOYD, John
Pennington, New Jersey 08534 (US)
 - MILLER, Michael Matthew
Pennington, New Jersey 08534 (US)
 - PI, Zulan
Pennington, New Jersey 08534 (US)
 - QIAO, Jennifer X.
Pennington, New Jersey 08534 (US)
 - RAMPULLA, Richard
Pennington, New Jersey 08534 (US)
 - WANG, Tammy C.
Pennington, New Jersey 08534 (US)
 - WANG, Yufeng
Pennington, New Jersey 08534 (US)
 - YANG, Wu
Pennington, New Jersey 08534 (US)
 - ROBERGE, Jacques Y.
Pennington, New Jersey 08534 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


EP 1 954 668 B9

EP 1 954 668 B9

[0867] It is noted that the proceeding examples, while illustrative of the present invention, are not in sequential order and some example numbers may be missing.


5 Claims

1. A compound of formula Ia or Ib




20 or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein:

A is:




EP 1 954 668 B9


5



10




15



20

25



30

35

40


45

50


55

EP 1 954 668 B9


5



10




15




20

25




30

35




40

45




50

55




EP 1 954 668 B9

5
10
15
20
25
30
35
40
45
50
55




EP 1 954 668 B9


5
10
15
20
25
30
35
40
45
50
55



B is:




EP 1 954 668 B9




R₁ is:

(a) -C(O)R₃, wherein R₃:




EP 1 954 668 B9


5




10




15




20




25




30




35




40



45




50




55

EP 1 954 668 B9


5




10




15




20



25




30




35

40




45

50



55


EP 1 954 668 B9



(b) -C(O)NHR₃, wherein the R₃ is:


EP 1 954 668 B9

5
10
15
20
25
30
35
40
45
50
55




EP 1 954 668 B9


5




10




15




20




25



30



35




40

45

50


55

EP 1 954 668 B9




EP 1 954 668 B9


5




10



15




20




25




30




35




40



45




50




55


EP 1 954 668 B9




5




10




15



25




30




35

(c) $-C(O)NR_2R_3$, wherein the NR_2R_3 is:




45




55

EP 1 954 668 B9




EP 1 954 668 B9


5



10




15



20


(e) $-\text{SO}_2\text{R}_5$ wherein the R_5 is:

25



(f) $-\text{CSNHR}_7$ wherein the R_7 is:


30




35

(g) $-\text{CH}_2\text{R}_8$ wherein the R_8 is:

40




45




50

55




EP 1 954 668 B9


5




10



15




20




25

30




35




40

45




50

55




EP 1 954 668 B9


5



10



15




20




25

30




35




40

45




50




55

EP 1 954 668 B9


5




10




15




20




25




30



35




40





45

50




55


EP 1 954 668 B9




(h) -C(S)R₃ wherein the R₃ is:



(i) -C(=NR₃)Oalkyl wherein the R₃ is:




2. A compound of formula Ia




or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein:


A is:




EP 1 954 668 B9




EP 1 954 668 B9



EP 1 954 668 B9




B is:




EP 1 954 668 B9


5




10




15




25




30



35



40




45


50

55

EP 1 954 668 B9




C is:




EP 1 954 668 B9


5




10




15




20



25




30



35

40




45


50

55


5




10




15




20




25




30



35



40




50


55

EP 1 954 668 B9


5




10



15




20




25

30




35

40




45




50

55


EP 1 954 668 B9



(b) -C(O)NHR₃, wherein the R₃ is:




EP 1 954 668 B9




EP 1 954 668 B9


5




10



15




20




25


30




35



40




45




50

55




EP 1 954 668 B9



5

(f) -CSNHR₇ wherein the R₇ is:


10




15

(g) -CH₂R₈ wherein the R₈ is:


20




25




30




35




40



45




50




55

EP 1 954 668 B9


5




10




15




20




25




30



35




45










50

55


EP 1 954 668 B9



EP 1 954 668 B9



(h) -C(S)R₃, wherein R₃:



EP 1 954 668 B9

3. A compound of claim 1, wherein the compound is selected from the group consisting of:

5

10

15

20

25

30

35

40

45

50

55

No.	Compound Name
2	(R)-4-Fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
56	(R)-4-fluoro-N-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
57	(S)-4-fluoro-N-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
59	(S)-N-(1-(3,4-difluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
60	(R)-N-(1-(3,4-difluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
61	(R)-4-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-methylbenzamide
62	(R)-3,4-difluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)benzamide
63	(R)-3-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)benzamide
64	(R)-3,5-difluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)benzamide
65	(R)-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
66	(R)-4-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
68	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
69	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
70	(R)-N-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
71	(S)-N-(1-(3-chloro-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
72	(S)-N-(1-(2,4-difluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
73	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(3-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
74	(S)-N-(1-(3-chloro-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
264	(R)-4-fluoro-N-(1-(4-fluoro-3-hydroxyphenyl)-1-(3-fluoro-5-(1,1,2,2)-tetrafluoro ethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
267	N-(1-(3-cyano-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
268	(R)-tert-butyl 2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzylcarbamate
269	(R)-N-(1-(3-(aminomethyl)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide hydrochloride
270	(R)-N-(1-(3-(acetamidomethyl)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
271	(R)-4-fluoro-N-(1-(4-fluoro-3-(methylsulfonamidomethyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
272	(R)-2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenyl methylcarbamate

No. Compound Name	
273	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5(1,1,2,2-tetrafluoro ethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
274	(R)-N-(1-(3-(1-amino-2-methyl-1-oxopropan-2-yloxy)-4-fluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
275	(R)-N-(1-(3-(2-cyanopropan-2-yloxy)-4-fluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
305	(R)-N-(1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
306	(R)-N-(1-(3-tert-butoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
309	(R)-N-(1-(3-cyclopropyl-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
310	(R)-4-fluoro-N-(1-(4-fluoro-3-isobutylphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
316	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,2,2-trifluorovinylloxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
337	2-amino-N-((R)-1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butanamide
338	(R)-N-(1-(3-cyclopentyl-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
339	(R)-methyl 2-(2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenoxy)-2-methylpropanoate
340	(R)-N-(1-(3-(benzylamino)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
341	(R,E)-methyl 3-(2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenyl)acrylate
344	((R)-4-fluoro-N-(1-(4-fluoro-3-(hydrazinecarbonyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
345	(R)-4-fluoro-N-(1-(4-fluoro-3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
348	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-(hydroxymethyl)phenyl)ethyl)-3-(trifluoromethyl)benzamide
349A	(R)-N-(1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
572	4-fluoro-N-(1-(4-fluoro-3-methylphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
579	(R)-4-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
580	4-fluoro-N-(1-(3-fluoro-4-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
586	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
587	(R)-methyl 5-(2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenoxy)pentanoate
588	(R)-4-fluoro-N-(1-(4-fluoro-3-(2-hydroxyethoxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
589	(R)-5-(2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenoxy)pentanoic acid

55	
50	
45	
40	
35	
30	
25	
20	
15	
10	
5	
(continued)	
No.	Compound Name
590	(R)-ethyl 2,2-difluoro-2-(2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenoxy)acetate
592	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-4-methoxy-3-(trifluoromethyl)benzamide
593	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-methoxybenzamide
607	(S)-N-(1-(3-bromo-4-fluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
610	(R)-N-(1-(3-ethoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
617	(S)-N-(1-(3-bromo-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
621	(R)-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
622	(R)-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
624	(R)-N-(1-(3-(cyclopentyloxy)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
626	(R)-N-(1-(3-(cyclohexylmethoxy)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
627	(R)-4-fluoro-N-(1-(4-fluoro-3-isobutoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
628	(R)-2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenyl propionate
629	(R)-4-fluoro-N-(1-(4-fluoro-3-(2,2,2-trifluoroethoxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
630	(R)-N-(1-(3-(cyclopropylmethoxy)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
631	(R)-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
632	(R)-2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenyl dimethylcarbamate
633	(R)-4-fluoro-N-(1-(3-fluoro-4-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
636	(R)-4-fluoro-N-(1-(4-fluoro-3-(3-hydroxy-2,2-dimethylpropoxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
637	(R)-4-fluoro-N-(1-(4-fluoro-3-propoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
638	(R)-N-(1-(3-(cyanomethoxy)-4-fluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
639	(R)-ethyl 2-(2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenoxy)-2-methylpropanoate
640	(R)-2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenyl isopropylcarbamate
641	(R)-2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenyl ethylcarbamate
642	N-((1R)-1-(3-(1-cyanoethoxy)-4-fluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
643	(R)-3-cyano-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)benzamide

89

		55	50	45	40	35	30	25	20	15	10	5
(continued)												
No.	Compound Name											
644	(R)-N-(1-(3-ethoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide											
645	(R)-2-(2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl)-1-(3-(trifluoromethyl)benzamido)ethyl)phenoxy)-2-methylpropanoic acid											
646	methyl 2-(2-fluoro-5-((R)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl)-1-(3-(trifluoromethyl)benzamido)ethyl)phenoxy)propanoate											
647	(R)-4,4,4-trifluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)butanamide											
648	(R)-4-fluoro-N-(1-(4-fluoro-3-isobutylphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide											
649	(R)-2-cyano-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)benzamide											
652	(R)-N-(1-(4-fluoro-3-(1-hydroxy-2-methylpropan-2-yloxy)phenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide											
653	(S)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide											
654	(S)-4-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide											
655	(S)-4-fluoro-N-(1-(4-fluoro-3-hydroxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide											
656	(R)-3-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide											
657	(R)-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethoxy)benzamide											
658	(R)-3,4-difluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide											
659	(R)-3-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide											
660	(R)-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethoxy)benzamide											
661	(R)-3,4-difluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide											
662	(R)-3-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-5-(trifluoromethyl)benzamide											
663	N-(1-(3-cyano-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide											
676	(R)-methyl 2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzylcarbamate											
677	(R)-N-(1-(3-cyclobutoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide											
678	N-((1R)-1-(3-((2,2-difluorocyclopropyl)methoxy)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide											
680	methyl 2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzoate											
681	(R)-4-fluoro-N-(1-(4-fluoro-3-neopentylphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide											

(continued)	
No.	Compound Name
684	(R)-N-(1-(3-((dimethylamino)methyl)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
687	2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-N-methylbenzamide
688	2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-N,N-dimethylbenzamide
690	methyl 2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzoate
694	(R)-2,4-difluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
695	(R)-4-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
696	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
697	(R)-2,4-difluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
700	(S)-4-fluoro-N-(1-(4-fluoro-3-(trifluoromethoxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
701	(R)-4-fluoro-N-(1-(4-fluoro-3-(trifluoromethoxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
708	2-(2-fluoro-5-((R)-1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenoxy)propanoic acid
709	4-fluoro-N-((1R)-1-(4-fluoro-3-(1-hydroxypropan-2-yloxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
710	(R)-4-fluoro-N-(1-(4-fluoro-3-(vinylloxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
711	(R)-4-fluoro-N-(1-(4-fluoro-3-(prop-1-en-2-yloxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
714	(R)-4-fluoro-N-(1-(4-fluoro-3-((isopropylamino)methyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
715	(R)-N-(1-(3-(cyclopropylamino)methyl)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
716	(R)-N-(1-(3-((butylamino)methyl)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
717	(R)-4-fluoro-N-(1-(4-fluoro-3-((isobutylamino)methyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
718	(R)-4-fluoro-N-(1-(4-fluoro-3-(morpholinomethyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
719	N-(1-(3-carbamoyl-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
720	(R)-4-fluoro-N-(1-(4-fluoro-3-((2-methoxyethylamino)methyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
726	(R)-4-fluoro-N-(1-(4-fluoro-3-(pyrrolidin-1-ylmethyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
728	(R)-N-(1-(3-cyclobutyl-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
729	(R)-4-fluoro-N-(1-(4-fluoro-3-isopentylphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
730	(R)-N-(1-(3-cyclohexyl-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide

(continued)	
No.	Compound Name
731	(R)-3-cyano-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
958	(S)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-(4-methoxyphenyl)ethyl)-3-(trifluoromethyl)benzamide
959	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-(4-methoxyphenyl)ethyl)-3-(trifluoromethyl)benzamide
960	(S)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)ethyl)-3-(trifluoromethyl)benzamide
961	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)ethyl)-3-(trifluoromethyl)benzamide
962	(R)-methyl 4-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)butanoate
963	(R)-4-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)butanoic acid
964	(S)-4-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)butanoic acid
965	(R)-methyl5-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)pentanoate
966	(R)-5-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)pentanoic acid
977	(R)-ethyl 6-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)hexanoate
978	(R)-6-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)hexanoic acid
983	(1r,4r)-4-(((4-((R)-2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)methyl)cyclohexanecarboxylic acid
985	(R)-7-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)heptanoic acid
1030	methyl4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(4-fluoro-3-isopropoxyphenyl)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)ethyl)benzoate
1031	4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-(hydroxymethyl)phenyl)ethyl)-3-(trifluoromethyl)benzamide
1032	N-(2-(4-carbamoylphenyl)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)ethyl)-4-fluoro-3-(trifluoromethyl)benzamide
1033	N-(2-(4-carbamoylphenyl)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)ethyl)-4-fluoro-3-(trifluoromethyl)benzamide
1034	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-(hydroxymethyl)phenyl)ethyl)-3-(trifluoromethyl)benzamide
1035	(R)-N-(2-(4-bromophenyl)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)ethyl)-4-fluoro-3-(trifluoromethyl)benzamide
1036	(S)-N-(2-(4-bromophenyl)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)ethyl)-4-fluoro-3-(trifluoromethyl)benzamide
1040	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-(2-hydroxypropan-2-yl)phenyl)ethyl)-3-(trifluoromethyl)benzamide
1041	(S)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-hydroxyphenyl)ethyl)-3-(trifluoromethyl)benzamide and
1042	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-hydroxyphenyl)ethyl)-3-(trifluoromethyl)benzamide,


EP 1 954 668 B9

stereoisomers or pharmaceutically acceptable salt forms thereof.

4. A compound of claim 3 that is (R)-N-(1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)-benzamide, stereoisomers and pharmaceutically acceptable salt forms thereof.
5. A compound of claim 3, wherein the compound is (R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide, stereoisomers and pharmaceutically acceptable salt forms thereof.
6. A compound of claim 3, wherein the compound is 2-amino-N-((R)-1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butanamide, stereoisomers and pharmaceutically acceptable salt forms thereof.
7. A pharmaceutical composition comprising a compound of any one of claims 1 to 6.
8. The pharmaceutical composition of claim 6 further comprising a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 7 further comprising at least one additional therapeutic agent.
10. A compound of any one of claims 1 to 6 for use in a method of inhibiting the cholesteryl ester transfer protein.
11. A compound of any one of claims 1 to 6 for use in a method for treating, preventing or slowing the progression of Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal.
12. A compound of any one of claims 1 to 6 for use in a method for treating, preventing or slowing the progression of a disease requiring cholesteryl ester transfer protein inhibitor therapy.
13. A compound of any one of claims 1 to 6 for use in a method for inhibiting remnant lipoprotein production.
14. A compound of any one of claims 1 to 6 for use in a method of raising HDL cholesterol in a mammal.

Patentansprüche

- 1. Verbindung der Formel Ia oder Ib**



oder Stereoisomere oder pharmazeutisch verträgliche Salzformen davon, worin:

A: